The role of g-protein-coupled receptor proteolysis site cleavage of polycystin-1 in renal physiology and polycystic kidney disease

Cells

Volumn 5, Issue 1, 2016, Pages

  Trudel, Marie ^a   Yao, Qin ^b   Qian, Feng ^b  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Adhesion GPCR; Cis autoproteolysis; GAIN domain; GPS motif; Polycystic kidney disease; Polycystin

Indexed keywords

G PROTEIN COUPLED RECEPTOR; LEUCINE RICH REPEAT KINASE 2; POLYCYSTIN 1;

BIOGENESIS; CELL MIGRATION; CELLULAR DISTRIBUTION; GENE EXPRESSION; GENE MUTATION; KIDNEY DEVELOPMENT; KIDNEY POLYCYSTIC DISEASE; NONHUMAN; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

EID: 85050577443     PISSN: None     EISSN: 20734409     Source Type: Journal    
DOI: 10.3390/cells5010003     Document Type: Review

References (67)

1. Harris, P.C.; Torres, V.E. Polycystic kidney disease. Annu. Rev. Med. 2009, 60, 321–337.
2. Consortium, T.E.P.K.D. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. Cell 1994, 77, 881–894.
3. Mochizuki, T.; Wu, G.; Hayashi, T.; Xenophontos, S.L.; Veldhuisen, B.; Saris, J.J.; Reynolds, D.M.; Cai, Y.; Gabow, P.A.; Pierides, A et al. Pkd2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 1996,272, 1339–1342.
4. Hughes, J.; Ward, C.J.; Peral, B.; Aspinwall, R.; Clark, K.; San Millan, J.L.; Gamble, V.; Harris, P.C. The polycystic kidney disease 1 (pkd1) gene encodes a novel protein with multiple cell recognition domains. Nat. Genet. 1995, 10, 151–160.
5. Igarashi, P.; Somlo, S. Genetics and pathogenesis of polycystic kidney disease. J. Am. Soc. Nephrol 2002, 13, 2384–2398.
6. Torres, V.E. New insights into polycystic kidney disease and its treatment. Curr. Opinion Nephrol. Hypertens. 1998, 7, 159–169.
7. Boyer, O.; Gagnadoux, M.F.; Guest, G.; Biebuyck, N.; Charbit, M.; Salomon, R.; Niaudet, P. Prognosis of autosomal dominant polycystic kidney disease diagnosed in utero or at birth. Pediatr. Nephrol. 2007, 22, 380–388.
8. Fick, G.M.; Johnson, A.M.; Strain, J.D.; Kimberling, W.J.; Kumar, S.; Manco-Johnson, M.L.; Duley, I.T.; Gabow, P.A. Characteristics of very early onset autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 1993, 3, 1863–1870.
9. Grantham, J.J.; Cook, L.T.; Wetzel, L.H.; Cadnapaphornchai, M.A.; Bae, K.T. Evidence of extraordinary growth in the progressive enlargement of renal cysts. Clin. J. Am. Soc. Nephrol. 2010, 5, 889–896.
10. Schroder, S.; Fraternali, F.; Quan, X.; Scott, D.; Qian, F.; Pfuhl, M. When a module is not a domain: The case of the rej module and the redefinition of the architecture of polycystin-1. Biochem. J. 2011, 435, 651–660.
11. Qian, F.; Wei, W.; Germino, G.; Oberhauser, A. The nanomechanics of polycystin-1 extracellular region. J. Biol. Chem.2005, 280, 40723–40730.
12. Ponting, C.P.; Hofmann, K.; Bork, P. A latrophilin/cl-1-like gps domain in polycystin-1. Curr. Biol. 1999, 9, R585–588.
13. Qian, F.; Boletta, A.; Bhunia, A.K.; Xu, H.; Liu, L.; Ahrabi, A.K.; Watnick, T.J.; Zhou, F.; Germino, G.G. Cleavage of polycystin-1 requires the receptor for egg jelly domain and is disrupted by human autosomal-dominant polycystic kidney disease 1-associated mutations. Proc. Natl. Acad. Sci. USA 2002, 99, 16981–16986.
14. Krasnoperov, V.G.; Bittner, M.A.; Beavis, R.; Kuang, Y.; Salnikow, K.V.; Chepurny, O.G.; Little, A.R.; Plotnikov, A.N.; Wu, D.; Holz, R.W et al. Alpha-latrotoxin stimulates exocytosis by the interaction with a neuronal g-protein-coupled receptor. Neuron 1997, 18, 925–937.
15. Arac, D.; Boucard, A.A.; Bolliger, M.F.; Nguyen, J.; Soltis, S.M.; Sudhof, T.C.; Brunger, A.T. A novel evolutionarily conserved domain of cell-adhesion gpcrs mediates autoproteolysis. EMBO J. 2012, 31, 1364–1378.
16. Bjarnadottir, T.K.; Fredriksson, R.; Hoglund, P.J.; Gloriam, D.E.; Lagerstrom, M.C.; Schioth, H.B. The human and mouse repertoire of the adhesion family of g-protein-coupled receptors. Genomics 2004, 84, 23–33.
17. Bjarnadottir, T.K.; Fredriksson, R.; Schioth, H.B. The adhesion gpcrs: A unique family of g protein-coupled receptors with important roles in both central and peripheral tissues. Cell. Mol. Life Sci. 2007, 64, 2104–2119.
18. 2+ signaling with implications for polycystic kidney disease. J. Biol. Chem. 2009, 284, 36431–36441.
19. 2+-dependent pathway(s). Exp. Cell Res. 2005, 304, 391–406.
20. Kim, E.; Arnould, T.; Sellin, L.K.; Benzing, T.; Fan, M.J.; Gruning, W.; Sokol, S.Y.; Drummond, I.; Walz, G. The polycystic kidney disease 1 gene product modulates wnt signaling. J. Biol. Chem. 1999, 274, 4947–4953.
21. Shillingford, J.M.; Murcia, N.S.; Larson, C.H.; Low, S.H.; Hedgepeth, R.; Brown, N.; Flask, C.A.; Novick, A.C.; Goldfarb, D.A.; Kramer-Zucker, A et al. The mtor pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc. Natl. Acad. Sci. USA 2006, 103, 5466–5471.
22. Rowe, I.; Chiaravalli, M.; Mannella, V.; Ulisse, V.; Quilici, G.; Pema, M.; Song, X.W.; Xu, H.; Mari, S.; Qian, F et al. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat. Med. 2013, 19, 488–493.
23. Menezes, L.F.; Zhou, F.; Patterson, A.D.; Piontek, K.B.; Krausz, K.W.; Gonzalez, F.J.; Germino, G.G. Network analysis of a pkd1-mouse model of autosomal dominant polycystic kidney disease identifies hnf4alpha as a disease modifier. PLoS Genetics 2012, 8, e1003053.
24. Parnell, S.C.; Magenheimer, B.S.; Maser, R.L.; Rankin, C.A.; Smine, A.; Okamoto, T.; Calvet, J.P. The polycystic kidney disease-1 protein, polycystin-1, binds and activates heterotrimeric g-proteins in vitro. Biochem. Biophys. Res. Commun.1998, 251, 625–631.
25. Parnell, S.C.; Magenheimer, B.S.; Maser, R.L.; Zien, C.A.; Frischauf, A.M.; Calvet, J.P. Polycystin-1 activation of c-jun n-terminal kinase and ap-1 is mediated by heterotrimeric g proteins. J. Biol. Chem. 2002, 277, 19566–19572.
26. Chauvet, V.; Tian, X.; Husson, H.; Grimm, D.H.; Wang, T.; Hiesberger, T.; Igarashi, P.; Bennett, A.M.; Ibraghimov-Beskrovnaya, O.; Somlo, S et al. Mechanical stimuli induce cleavage and nuclear translocation of the polycystin-1 c terminus. J. Clin. Invest. 2004, 114, 1433–1443.
27. Merrick, D.; Chapin, H.; Baggs, J.E.; Yu, Z.; Somlo, S.; Sun, Z.; Hogenesch, J.B.; Caplan, M.J. The gamma-secretase cleavage product of polycystin-1 regulates tcf and chop-mediated transcriptional activation through a p300-dependent mechanism. Dev. Cell 2012, 22, 197–210.
28. Hanaoka, K.; Qian, F.; Boletta, A.; Bhunia, A.K.; Piontek, K.; Tsiokas, L.; Sukhatme, V.P.; Guggino, W.B.; Germino, G.G. Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents. Nature 2000, 408, 990–994
29. Qian, F.; Germino, F.J.; Cai, Y.; Zhang, X.; Somlo, S.; Germino, G.G. Pkd1 interacts with pkd2 through a probable coiled-coil domain. Nat. Genet. 1997, 16, 179–183.
30. Tsiokas, L.; Kim, E.; Arnould, T.; Sukhatme, V.P.; Walz, G. Homo- and heterodimeric interactions between the gene products of pkd1 and pkd2. Proc. Natl. Acad. Sci. USA 1997, 94, 6965–6970.
31. Nauli, S.M.; Alenghat, F.J.; Luo, Y.; Williams, E.; Vassilev, P.; Li, X.; Elia, A.E.; Lu, W.; Brown, E.M.; Quinn, S.J et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat. Genet. 2003, 33, 129–137.
32. Pazour, G.J. Intraflagellar transport and cilia-dependent renal disease: The ciliary hypothesis of polycystic kidney disease. J. Am. Soc. Nephrol. 2004, 15, 2528–2536.
33. Yoder, B.K. Role of primary cilia in the pathogenesis of polycystic kidney disease. J. Am. Soc. Nephrol. 2007, 18, 1381–1388.
34. Yoder, B.K.; Hou, X.; Guay-Woodford, L.M. The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J. Am. Soc. Nephrol. 2002, 13, 2508–2516.
35. Delling, M.; DeCaen, P.G.; Doerner, J.F.; Febvay, S.; Clapham, D.E. Primary cilia are specialized calcium signalling organelles. Nature 2013, 504, 311–314.
36. Qian, F. Polycystin-1, The Handbook of Proteolytic Enzymes, 3rd ed.; Elsevier: Oxford, UK, 2013; Volume 3, pp. 3728–3736.
37. Wei, W.; Hackmann, K.; Xu, H.; Germino, G.; Qian, F. Characterization of cis-autoproteolysis of polycystin-1, the product of human polycystic kidney disease 1 gene. J. Biol. Chem. 2007, 30, 21729–21737.
38. Lin, H.H.; Chang, G.W.; Davies, J.Q.; Stacey, M.; Harris, J.; Gordon, S. Autocatalytic cleavage of the emr2 receptor occurs at a conserved g protein-coupled receptor proteolytic site motif. J. Biol. Chem. 2004, 279, 31823–31832.
39. Kurbegovic, A.; Kim, H.; Xu, H.; Yu, S.; Cruanes, J.; Maser, R.L.; Boletta, A.; Trudel, M.; Qian, F. Novel functional complexity of polycystin-1 by gps cleavage in vivo: Role in polycystic kidney disease. Mol. Cell. Biol. 2014, 34, 3341–3353.
40. Yu, S.; Hackmann, K.; Gao, J.; He, X.; Piontek, K.; Garcia-Gonzalez, M.A.; Menezes, L.F.; Xu, H.; Germino, G.G.; Zuo, J et al. Essential role of cleavage of polycystin-1 at g protein-coupled receptor proteolytic site for kidney tubular structure. Proc. Natl. Acad. Sci. USA 2007, 104, 18688–18693.
41. Castelli, M.; Boca, M.; Chiaravalli, M.; Ramalingam, H.; Rowe, I.; Distefano, G.; Carroll, T.; Boletta, A. Polycystin-1 binds par3/apkc and controls convergent extension during renal tubular morphogenesis. Nat. Commun. 2013, 4, 2658.
42. Ahrabi, A.K.; Jouret, F.; Marbaix, E.; Delporte, C.; Horie, S.; Mulroy, S.; Boulter, C.; Sandford, R.; Devuyst, O. Glomerular and proximal tubule cysts as early manifestations of pkd1 deletion. Nephrol. Dial. Transpl. 2010, 25, 1067–1078.
43. Lu, W.; Shen, X.; Pavlova, A.; Lakkis, M.; Ward, C.J.; Pritchard, L.; Harris, P.C.; Genest, D.R.; Perez-Atayde, A.R.; Zhou, J. Comparison of pkd1-targeted mutants reveals that loss of polycystin-1 causes cystogenesis and bone defects.Hum. Mol. Genet. 2001, 10, 2385–2396.
44. Piontek, K.B.; Huso, D.L.; Grinberg, A.; Liu, L.; Bedja, D.; Zhao, H.; Gabrielson, K.; Qian, F.; Mei, C.; Westphal, H et al. A functional floxed allele of pkd1 that can be conditionally inactivated in vivo. J. Am. Soc. Nephrol. 2004, 15, 3035–3043.
45. Jiang, S.T.; Chiou, Y.Y.; Wang, E.; Lin, H.K.; Lin, Y.T.; Chi, Y.C.; Wang, C.K.; Tang, M.J.; Li, H. Defining a link with autosomal-dominant polycystic kidney disease in mice with congenitally low expression of pkd1. Am. J. Pathol. 2006,168, 205–220.
46. Lin, F.; Hiesberger, T.; Cordes, K.; Sinclair, A.M.; Goldstein, L.S.; Somlo, S.; Igarashi, P. Kidney-specific inactivation of the kif3a subunit of kinesin-ii inhibits renal ciliogenesis and produces polycystic kidney disease. Proc. Natl. Acad. Sci. USA 2003, 100, 5286–5291.
47. Jonassen, J.A.; San Agustin, J.; Follit, J.A.; Pazour, G.J. Deletion of ift20 in the mouse kidney causes misorientation of the mitotic spindle and cystic kidney disease. J. Cell. Biol. 2008, 183, 377–384.
48. Lantinga-van Leeuwen, I.S.; Dauwerse, J.G.; Baelde, H.J.; Leonhard, W.N.; van de Wal, A.; Ward, C.J.; Verbeek, S.; Deruiter, M.C.; Breuning, M.H.; de Heer, E et al. Lowering of pkd1 expression is sufficient to cause polycystic kidney disease. Hum. Mol. Genet. 2004, 13, 3069–3077.
49. Tesmer, J.J. A gain in understanding autoproteolytic g protein-coupled receptors and polycystic kidney disease proteins. EMBO J. 2012, 31, 1334–1335.
50. Paavola, K.J.; Stephenson, J.R.; Ritter, S.L.; Alter, S.P.; Hall, R.A. The n terminus of the adhesion g protein-coupled receptor gpr56 controls receptor signaling activity. J. Biol. Chem. 2011, 286, 28914–28921.
51. Ward, Y.; Lake, R.; Yin, J.J.; Heger, C.D.; Raffeld, M.; Goldsmith, P.K.; Merino, M.; Kelly, K. Lpa receptor heterodimerizes with cd97 to amplify lpa-initiated rho-dependent signaling and invasion in prostate cancer cells.Cancer Res. 2011, 71, 7301–7311.
52. Paavola, K.J.; Hall, R.A. Adhesion g protein-coupled receptors: Signaling, pharmacology, and mechanisms of activation. Mol. Pharmacol. 2012, 82, 777–783.
53. Kim, H.; Xu, H.; Yao, Q.; Li, W.; Huang, Q.; Outeda, P.; Cebotaru, V.; Chiaravalli, M.; Boletta, A.; Piontek, K et al. Ciliary membrane proteins traffic through the golgi via a rabep1/gga1/arl3-dependent mechanism. Nat. Commun.2014, 5, 5482.
54. Puertollano, R.; Randazzo, P.A.; Presley, J.F.; Hartnell, L.M.; Bonifacino, J.S. The ggas promote arf-dependent recruitment of clathrin to the tgn. Cell 2001, 105, 93–102.
55. Schrick, J.J.; Vogel, P.; Abuin, A.; Hampton, B.; Rice, D.S. Adp-ribosylation factor-like 3 is involved in kidney and photoreceptor development. Am. J. Pathol. 2006, 168, 1288–1298.
56. Cai, Y.; Fedeles, S.V.; Dong, K.; Anyatonwu, G.; Onoe, T.; Mitobe, M.; Gao, J.D.; Okuhara, D.; Tian, X.; Gallagher, A.R et al. Altered trafficking and stability of polycystins underlie polycystic kidney disease. J. Clin. Invest. 2014, 124, 5129–5144.
57. Xu, Q.; Buckley, D.; Guan, C.; Guo, H.C. Structural insights into the mechanism of intramolecular proteolysis. Cell 1999, 98, 651–661.
58. Garcia-Gonzalez, M.A.; Jones, J.G.; Allen, S.K.; Palatucci, C.M.; Batish, S.D.; Seltzer, W.K.; Lan, Z.; Allen, E.; Qian, F.; Lens, X.M et al. Evaluating the clinical utility of a molecular genetic test for polycystic kidney disease. Mol. Genet. Metab 2007, 92, 160–167.
59. Hopp, K.; Ward, C.J.; Hommerding, C.J.; Nasr, S.H.; Tuan, H.F.; Gainullin, V.G.; Rossetti, S.; Torres, V.E.; Harris, P.C. Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. J. Clin. Invest. 2012,122, 4257–4273.
60. Harris, P.C.; Torres, V.E. Understanding pathogenic mechanisms in polycystic kidney disease provides clues for therapy. Curr. Opin. Nephrol. Hy. 2006, 15, 456–463.
61. Torres, V.E.; Wang, X.; Qian, Q.; Somlo, S.; Harris, P.C.; Gattone, V.H., 2nd. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat. Med. 2004, 10, 363–364.
62. Czarnecki, P.G.; Steinman, T.I. Polycystic kidney disease: New horizons and therapeutic frontiers. Minerva Urol. Nefrol. 2013, 65, 61–68
63. Baur, B.P.; Meaney, C.J. Review of tolvaptan for autosomal dominant polycystic kidney disease. Pharmacotherapy 2014,34, 605–616.
64. Watnick, T.; Germino, G.G. Mtor inhibitors in polycystic kidney disease. N. Engl. J. Med. 2010, 363, 879–881.
65. Holleran, J.P.; Zeng, J.; Frizzell, R.A.; Watkins, S.C. Regulated recycling of mutant cftr is partially restored by pharmacological treatment. J. Cell Sci. 2013, 126 Pt.12, 2692–2703.
66. Morello, J.P.; Salahpour, A.; Laperriere, A.; Bernier, V.; Arthus, M.F.; Lonergan, M.; Petaja-Repo, U.; Angers, S.; Morin, D.; Bichet, D.G et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded v2 vasopressin receptor mutants. J. Clin. Invest. 2000, 105, 887–895.
67. Virant-Young, D.; Thomas, J.; Woiderski, S.; Powers, M.; Carlier, J.; McCarty, J.; Kupchick, T.; Larder, A. Cystic fibrosis: A novel pharmacologic approach to cystic fibrosis transmembrane regulator modulation therapy. J. Am. Osteopath. Assoc. 2015, 115, 546–555.